This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Axial Spondyloarthritis Registry

  • Research type

    Research Study

  • Full title

    Axial Spondyloarthritis Registry

  • IRAS ID

    152445

  • Contact name

    Nicola Goodson

  • Contact email

    ngoodson@liv.ac.uk

  • Duration of Study in the UK

    3 years, 0 months, 0 days

  • Research summary

    Axial spondyloarthritis (axSpA) is a group of inflammatory diseases that cause arthritis of the spine. They tend to affect younger patients and can be disabling and difficult to manage.
    The most common axSpA is ankylosing spondylitis (AS), which affects around 1 in 1,000 people in the UK. In addition to the spine, axSpA can affect the attachment sites of tendons and ligaments to bone (enthesitis), bowels (IBD), and the eyes (uveitis).

    Chronic inflammation in axSpA can lead to development of other disease burdens (comorbidities). The most common comorbidities are osteoporosis (thinning of the bones) and cardiovascular diseases (CVD). Identifying and understanding them will improve the management of this condition.

    At Aintree University Hospital, the rheumatology department keeps a pseudo-anonymised clinical audit database with the aim of improving quality of care and the systematic enquiry and documentation relating to CVD, IBD, osteoporosis and treatment response. Data is entered from electronic casenotes and clinic letters. By designing a protocol which securely extracts fully anonymised data, The wealth of data stored on this database is invaluable for answering many epidemiological questions.

    The aim of this study is to use fully anonymised data from the clinical audit database to answer the following observational research questions for this patient population:

    1. What is the prevalence of, and risk factors for, osteoporosis/osteopenia and how effective is antero-posterior DEXA scans in their diagnosis.
    2. What is the effect of cigarette smoking on disease activity and response to anti-TNF therapy.
    3. What is the prevalence of vitamin D deficiency/insufficiency and relationship with disease activity and response to anti-TNF therapy.
    4. What is the prevalence and characteristics of gastro-intestinal symptoms.

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    15/LO/1519

  • Date of REC Opinion

    26 Aug 2015

  • REC opinion

    Further Information Favourable Opinion